B022 is a potent and selective NF-κB-induced kinase (NIK) inhibitor with a Ki of 4.2 nM. B022 protects the liver from inflammation, oxidative stress and damage caused by toxins.

 

Brand: BCM

 

Target: NF-κB

 

Signaling Pathways: NF-κB

 

In Vitro: B022 (0-5 μM; 12 hours; Hepa1 cells) treatment for 8 h completely blocks NIK-induced expression of TNF-a, IL-6, iNOS, CCL2, and CXCL5[1]. B022 (0-5 μM; 12 hours; Hepa1 cells) treatment suppresses NIK-induced p52 formation in a dose-dependent manner.

 

In Vivo: B022 (30 mg/kg; intravenous injection; twice a day; for 10 days; STOP-NIK male mice) treatment inhibits NIK-triggered liver inflammation and injury in STOP-NIK mice infected with cre adenoviruses.

 

Boiling Point: 644.4±65.0 °C(Predicted)

 

pKa: 10.71±0.29(Predicted)

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

Isomeric SMILES: CC(C#CC1=CC2=C(CCN2C3=NC(=NC=C3Cl)N)C=C1)(C4=NC=CS4)O  

 

InChIKey: OKFYOOFXVBCIIP-UHFFFAOYSA-N  

 

InChI: InChI=1S/C19H16ClN5OS/c1-19(26,17-22-7-9-27-17)6-4-12-2-3-13-5-8-25(15(13)10-12)16-14(20)11-23-18(21)24-16/h2-3,7,9-11,26H,5,8H2,1H3,(H2,21,23,24) 

 

Attribute
[Chem Name]	4-[1-(2-amino-5-chloropyrimidin-4-yl)-2,3-dihydroindol-6-yl]-2-(1,3-thiazol-2-yl)but-3-yn-2-ol
[Synonym]	B022
[CAS No.]	1202764-53-1
[MDL No.]	MFCD32645350
[Formula]	C19H16ClN5OS
[Molecular]	397.88
[Form]	Solid Powder
[Storage]	Sealed in dry. Stored at -20°C.

Goods Tag